According to the UK SmPC, the most common side effects include: Nausea (very common, affecting more than 1 in 10 people): Usually most pronounced during the first few weeks of treatment and often diminishes with continued use Diarrhoea (common, affecting up to 1 in 10 people): Typically mild to moderate in severity Vomiting (common): More frequent at higher doses Constipation (common): May occur alongside other gastrointestinal effects Abdominal pain or discomfort (common): Relatively frequent during treatment initiation Decreased appetite (very common): An expected effect related to the medication's action Dyspepsia/indigestion (common): May contribute to discomfort after eating Beyond gastrointestinal effects, other recognised adverse reactions include injection site reactions (redness, itching, or swelling at the subcutaneous injection site), fatigue , and dizziness
When testing each drug type separately, we estimate the effect of the SNP on BMI % to be larger in tirzepatide (effect = 0.95%) than semaglutide (effect = 0.51%), although the 95% confidence intervals were overlapping (Extended Data Fig
That is a meaningful regulatory distinction and something every patient should understand clearly before starting
Scar tissue doesnt always blend in with surrounding skin, causing a visible shelf in certain cases
Injections win for consistent dosing and trial-backed schedules
Bioengineered 13, 25132524
